These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32954565)

  • 41. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
    Lane S; Lynn E; Shakir S
    BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
    Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.
    Pacurariu A; Plueschke K; McGettigan P; Morales DR; Slattery J; Vogl D; Goedecke T; Kurz X; Cave A
    BMJ Open; 2018 Sep; 8(9):e023090. PubMed ID: 30185579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patient Reporting in the EU: Analysis of EudraVigilance Data.
    Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
    Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EU alerting and reporting systems for potential chemical public health threats and hazards.
    Orford R; Crabbe H; Hague C; Schaper A; Duarte-Davidson R
    Environ Int; 2014 Nov; 72():15-25. PubMed ID: 25023642
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers.
    Klein K; De Bruin ML; Broekmans AW; Stolk P
    BioDrugs; 2015 Dec; 29(6):373-9. PubMed ID: 26621793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee.
    Flynn R; Hedenmalm K; Murray-Thomas T; Pacurariu A; Arlett P; Shepherd H; Myles P; Kurz X
    Clin Pharmacol Ther; 2020 Apr; 107(4):957-965. PubMed ID: 31955404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biosimilars: pharmacovigilance and risk management.
    Zuñiga L; Calvo B
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Translation and introduction of Guide to Methodological Standards in Pharmacoepidemiology].
    Tian F; Liao X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2949-57. PubMed ID: 24471310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparative analysis of the pharmacovigilance systems of Brazil, Spain, the European Union and the United States based on the information provided by their regulatory agency websites.
    Leal MM; Sanz MM; Ferrando JRC; Martinez-Martinez F
    Daru; 2019 Jun; 27(1):379-387. PubMed ID: 30778915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk management : a European regulatory perspective.
    Moseley JN
    Drug Saf; 2004; 27(8):499-508. PubMed ID: 15154823
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Herbal medicines: challenges in the modern world. Part 2. European Union and Russia.
    Sammons HM; Gubarev MI; Krepkova LV; Bortnikova VV; Corrick F; Job KM; Sherwin CM; Enioutina EY
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1117-27. PubMed ID: 27171366
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.
    Baldo P; Francescon S; Fornasier G
    Int J Clin Pharm; 2018 Aug; 40(4):748-753. PubMed ID: 30094557
    [TBL] [Abstract][Full Text] [Related]  

  • 58. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety signal detection: the relevance of literature review.
    Pontes H; Clément M; Rollason V
    Drug Saf; 2014 Jul; 37(7):471-9. PubMed ID: 24895178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nimesulide controversy: a comparison of EU and Indian scenario.
    Kshirsagar NA; Bachhav SS
    Int J Risk Saf Med; 2013; 25(4):239-46. PubMed ID: 24305563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.